Please login to the form below

Not currently logged in
Email:
Password:

Michael Le Brocq joins Langland

Takes up role as business unit director

Michael Le Brocq joins LanglandWindsor, UK-based healthcare advertising agency Langland has appointed Michael Le Brocq as business unit director (ethical).

Joining from ICC Lowe London, where he was head of strategy, Le Brocq has held senior pharmaceutical marketing roles at Parke-Davis (Pfizer), Novartis and Stiefel. 

Le Brocq was also commercial director and chief operating officer at Virgin Health Bank - Sir Richard Branson's first venture into the healthcare services sector. 

“We are delighted that Michael has joined Langland,” said chief executive Philip Chin. 

“His significant experience on both client and agency side means that we will be even more focused in our delivery of commercially effective and innovative communication solutions to our clients.” 

Le Brocq also joins the agency's management team. Langland's management has seen significant change in recent months, including Alison Ferrucci's appointment as strategic delivery director. 

In April Kate Spencer was made managing partner and Andrew Spurgeon promoted to executive creative director. 

Langland, which was named Global Agency of the Year at the 2013 Global Awards for the third consecutive year, counts Lilly, Celgene and Bayer among its clients.

16th June 2014

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics